| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/16/2005 | CN1582164A Antigen arrays for treatment of bone disease |
| 02/16/2005 | CN1582162A Thymosin alpha 1 peptide/polymer conjugates |
| 02/16/2005 | CN1582161A Pharmatceutical Formualtion comprising cyclosporin and use thereof |
| 02/16/2005 | CN1582159A Preparing material of flavanol wood lipid with increased solubility |
| 02/16/2005 | CN1582158A Novel therapeutic indication of azithromycin for treatment of non-infective inflammatory diseases |
| 02/16/2005 | CN1582155A Ribavirin syrup formulations |
| 02/16/2005 | CN1582145A Extended release pharmaceutical composition containing metformin |
| 02/16/2005 | CN1582144A Process for preparing dry extracts |
| 02/16/2005 | CN1582143A Pro-micelle pharmaceutical compositions |
| 02/16/2005 | CN1582142A Ibuprofen salt emulsifiers and cream formulations containing same |
| 02/16/2005 | CN1579552A Polymer-made-micel contained administration system through skin or mucosa |
| 02/16/2005 | CN1579412A Cytidine triphosphate disodium chloride injecta and its preparation process |
| 02/16/2005 | CN1579410A Oral total notoginsenoside blending preparation |
| 02/16/2005 | CN1579409A Oral total notoginsenoside slow-releasing preparation |
| 02/16/2005 | CN1579401A Cought and asthma relieaving preparation and its preparation method |
| 02/16/2005 | CN1579396A Slow-releasing medicine inplanted in eye and use thereof |
| 02/16/2005 | CN1579394A composition for relieving nausea and vomiting induced from chemotherapy for cancer patient |
| 02/16/2005 | CN1189476C New thrombin inhibitors, their preparation and use |
| 02/16/2005 | CN1189216C Pharmaceutical compositions containing plasma protein |
| 02/16/2005 | CN1189215C Composition and formulation for solubilizing multiple compounds and preparation method thereof |
| 02/16/2005 | CN1189210C Coupling object between CB and biological active peptide as well as medication usage thereof |
| 02/16/2005 | CN1189171C Hydrophilic molecular disperse solutions of carvedilol |
| 02/16/2005 | CN1189165C Fast-acting analgesic |
| 02/16/2005 | CN1189161C Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral adminisration thereof |
| 02/16/2005 | CN1189159C Micro-capsule contg. water soluble beauty-care activity component water nuclear, and composition contg. same |
| 02/15/2005 | US6855860 Nonocclusive dressing comprising natural polymer fibers and a synthetic polymer foam layer having a pore-containing surface physically interlocked with the fibers; separation; nonadhesive; easy to manufacture; nontoxic; permeability |
| 02/15/2005 | US6855810 Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof |
| 02/15/2005 | US6855770 Drug delivery compositions and medical devices containing block copolymer |
| 02/15/2005 | US6855693 Peptide for use in the treatment of cell damage caused by ischemia |
| 02/15/2005 | US6855691 Methods for producing and using S-nitrosohemoglobins |
| 02/15/2005 | US6855689 Anticancer agents |
| 02/15/2005 | US6855688 ADP-ribosyl transferase fusion proteins, pharmaceutical compositions, and methods of use |
| 02/15/2005 | US6855687 Administering to the site in need of cartilage repair a polypeptide having the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gl y-Asp-Ser-Pro-Phe-Val |
| 02/15/2005 | US6855549 Methods and compositions for increasing the infectivity of gene transfer vectors |
| 02/15/2005 | US6855342 Compositions and methods for high sorption of skin materials and delivery of sulfur |
| 02/15/2005 | US6855334 Controlled delivery of active agents |
| 02/15/2005 | US6855332 Polyoxyethylene glycol, fatty acid mono- and diglyceride ester especially for intranasal administration of, e.g., antiemetics or migraine treating agents |
| 02/15/2005 | US6855329 Biodegradable and biocompatible article with a active ligand bount to the surface in a spatially controlled pattern by means of an adaptor compound attached to the surface by reaction with an anchor molecule; tissue engineering template |
| 02/15/2005 | US6855326 Skin disorders; protective coatings |
| 02/15/2005 | US6855321 Polyepitope carrier protein |
| 02/15/2005 | US6855310 Aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of acetaminophen, orphenadrine or tramadol. |
| 02/15/2005 | US6855277 Method and apparatus for liposome production |
| 02/15/2005 | CA2421026C Viral inhibition by n-docosanol |
| 02/15/2005 | CA2156408C Aerosol formulation containing a polyester dispersing aid |
| 02/12/2005 | CA2437266A1 Taste-masked resinate and preparation thereof |
| 02/12/2005 | CA2436979A1 Methods for preventing neurological events |
| 02/10/2005 | WO2005012870A2 Improved aminodextran compositions and conjugates and methods of making and using them |
| 02/10/2005 | WO2005012495A2 Methods for expression and purification of immunotoxins |
| 02/10/2005 | WO2005012488A2 Compositions for encapsulation and controlled release |
| 02/10/2005 | WO2005012484A2 Antibody-toxin conjugates |
| 02/10/2005 | WO2005012479A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/10/2005 | WO2005012470A1 Antioxidative composition |
| 02/10/2005 | WO2005012407A2 Polymer encapsulation of adenoviruses |
| 02/10/2005 | WO2005012346A1 Long lasting insulin derivatives and methods thereof |
| 02/10/2005 | WO2005012335A1 Imaging agents |
| 02/10/2005 | WO2005012176A1 Highly oil absorbing amorphous silica particles |
| 02/10/2005 | WO2005012175A1 Amorphous silica particles having high absorbing capabilities and high structural characteristics |
| 02/10/2005 | WO2005011740A1 Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions |
| 02/10/2005 | WO2005011739A1 Use of recombinant or synthetic gelatin as a stabiliser in vaccines |
| 02/10/2005 | WO2005011738A2 Polymeric conjugates containing phosphine - based chelating groups |
| 02/10/2005 | WO2005011737A2 Pharmaceutical combinations and formulations with improved stability |
| 02/10/2005 | WO2005011713A1 Sealing of bacterial ghosts by means of bioaffinity interactions |
| 02/10/2005 | WO2005011708A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| 02/10/2005 | WO2005011704A1 Product containing prostaglandin |
| 02/10/2005 | WO2005011688A1 Cci-779 lyophilized formulations |
| 02/10/2005 | WO2005011683A1 Transdermal absorption preparation |
| 02/10/2005 | WO2005011682A1 Sustained release tablet for oral use |
| 02/10/2005 | WO2005011669A1 Medicinal composition for percutaneous administration |
| 02/10/2005 | WO2005011662A1 Adhesive patch |
| 02/10/2005 | WO2005011641A2 Improved stearate composition and method of production thereof |
| 02/10/2005 | WO2005011637A1 At-use dispersed preparation |
| 02/10/2005 | WO2005011635A2 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 02/10/2005 | WO2005011633A1 Remedy or diagnostic for inflammatory disease containing target-directing liposome |
| 02/10/2005 | WO2005011632A1 Target-directed and enteric absorption-controlled liposome having sugar chain and cancer remedy and diagnostic containing the same |
| 02/10/2005 | WO2005011631A1 Dialysis solutions with reduced levels of glucose degradation products |
| 02/10/2005 | WO2005011629A1 Bioactive compositions comprising triazines |
| 02/10/2005 | WO2005011610A2 Neurodegenerative protein aggregation inhibition methods and compounds |
| 02/10/2005 | WO2005011584A2 Decorin proteoglycan inhibitor of fibrinogen blood clotting |
| 02/10/2005 | WO2005011575A2 Stabilization and ionic triggering of nitric oxide release |
| 02/10/2005 | WO2004108634A3 Reagents for modifying biopharmaceuticals, the use and production thereof |
| 02/10/2005 | WO2004087117A3 Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs |
| 02/10/2005 | WO2004073652A3 Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| 02/10/2005 | WO2004065440B1 Cationic graft-copolymer for non-viral gene delivery vector |
| 02/10/2005 | WO2004050016A3 Delivery of pharmaceutical agents via the human insulin receptor |
| 02/10/2005 | WO2004039830A3 Bioactivation of particles |
| 02/10/2005 | WO2003099338A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 02/10/2005 | US20050033058 Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| 02/10/2005 | US20050033034 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 02/10/2005 | US20050033026 Immunoconjugates for the treatment of tumours |
| 02/10/2005 | US20050032929 Maleic anhydride-methyl vinyl ether copolymers; polyamic acids; medical implant device, dressing, scaffold, or fluid adhesive for treatment or prophylaxis of wounds; enhanced activity of protease inhibitors and neurotransmitter drugs |
| 02/10/2005 | US20050032914 Lutein/zeaxanthin for glare protection |
| 02/10/2005 | US20050032912 Inhalation formulation of a suspension of the anaesthetic agent such as enflurane, desflurane, propofol in aqueous medium; without the problem of condensation of the anaesthetic within the administration apparatus and/or delivery tubes to the patient |
| 02/10/2005 | US20050032910 Including keloid and hypertrophic scars; use in hydroalcoholic solutions and hydroalcoholic gels |
| 02/10/2005 | US20050032909 Treatment of mastalgia with 4-hydroxy tamoxifen |
| 02/10/2005 | US20050032900 For topical administration, without the presence of conventional oil in water (O/W) emulsifying agent; percutaneous delivery of ibuprofen is improved by using a skin penetration enhancer, such as 2-n-nonyl-1,3-dioxolane or decanal, dimethyl acetal, as the oily phase of the emulsion |
| 02/10/2005 | US20050032895 Medicament for the treatment of viral skin and tumour diseases |
| 02/10/2005 | US20050032893 For topical administration; (N,N-dimethylamino)isopropyl propylene glycol heptadecanoate for example; penetration enhancers have hydrophobic fatty acyl group and hydrophilic dimethylamino and alkylene glycol diester groups |
| 02/10/2005 | US20050032867 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 02/10/2005 | US20050032852 1-(N-substituted sulfonamido),4-(substituted isooxazoly-4-yl)benzenes, e.g., N-ethyl-4-(5-methyl-3-phenylisoxazol-4-yl)-N-propionylbenzenesulfonamide; side effect reduction; solubility; stability; bioavailability, i.e., readily penetrate membranes; non-steroidal antiinflammatory agents; analgesics |
| 02/10/2005 | US20050032811 Composition comprising aripiprazole and a carrier such as carboxymethyl cellulose administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent; efficiency |